================================================================================
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                       Securities and Exchange Act of 1934

         Date of report (Date of earliest event reported): June 12, 2001

                              DELCATH SYSTEMS, INC.
                              ---------------------
             (Exact name of registrant as specified in its charter)

                                    Delaware
                                    --------
                            (State of incorporation)

                001-16133                   06-1245881
                ---------                   ----------
          (Commission File No.)    (IRS Employer Identification No.)

                               1100 Summer Street
                           Stamford, Connecticut 06905
                           ---------------------------
              (Address of principal executive offices and zip code)

       Registrant's telephone number, including area code: (203) 323-8668



================================================================================


Item 5.   OTHER EVENTS

On June 12, 2001, Delcath Systems, Inc. announced that The National Cancer
Institute ("NCI") approved a clinical study protocol for administering
escalating doses of melphalan through the Delcath drug delivery system to
patients with unresectable cancer of the liver.

The protocol's approval, relayed verbally by the NCI attorney and announced here
today at the Company's annual meeting, sets the stage for an NCI-sponsored study
to determine the maximally tolerated dose of melphalan administered via isolated
perfusion through the Delcath system. The study will also help establish
protocols of an anticipated Phase III trial with melphalan.

In earlier work unrelated to Delcath, NCI researchers reported significant tumor
reduction and prolonged survival among patients with cancer of the liver who had
undergone isolated perfusion therapy with melphalan alone or in combination with
other antitumor agents.

The Delcath system, a relatively new advance in perfusion technology, is said to
be far less invasive than techniques used earlier by NCI surgeons. More
importantly, the Delcath treatment is repeatable, so patients who respond to the
therapy can continue to receive treatments to keep their tumors in check. The
patented system allows high doses of a drug to be infused directly into the
liver along with the organ's normal blood supply. The procedure is non-surgical
and does not interrupt the natural circulation of blood within the patient.

The NCI's most recent studies with isolated liver perfusion techniques have
involved a lengthy (6-7 hour) surgical procedure in which the right and left
lobes of the liver are severed from their diaphragmatic attachments and various
tubes and clamps are installed as part of a complex procedure to achieve
complete vascular isolation of the organ, thus limiting systemic absorption of
the anticancer drug. The mean hospital stay for this surgery is reported to be
11 days.

                                      -2-


By contrast, the Delcath system is designed to achieve vascular isolation of the
organ in an outpatient setting with a minimally invasive, non-surgical
procedure. The system removes the majority of the drug from the blood through a
sophisticated catheterization and filtration process.

At the request of the NCI, Delcath demonstrated that its system removes 99.9
percent of melphalan from blood in a laboratory setting.

"The NCI protocol put us on a course to make melphalan the second drug for
advanced study with the Delcath system," said M.S. Koly, Delcath's chief
executive officer. "We have completed Phase I/II tests with high doses of
doxorubicin in patients with cancer of the liver and we will commence a Phase
III pivotal trial with the drug later this year."

Up to 27 patients with unresectable malignancies in the liver will be treated
under the NCI's dose-escalating protocol. A group of three patients will be
treated at 60 mg/square meter of melphalan, the lowest study dose, and up to
four additional groups of three patients could each receive 90, 110, 130 and 150
mg/square meter until clinicians observe unallowable toxicity and thereby
establish the maximum safe tolerated dose.

The NCI's Surgical Metabolism Section has been studying a role for isolated
perfusion in the treatment of patients with cancer of the liver for
approximately eight years and believes the Delcath system may potentially expand
the number of patients eligible for perfusion therapy with high dose melphalan.

H. Richard Alexander, MD of the NCI's Surgery Branch, notes "many patients with
unresectable liver malignancies are not ideal candidates for isolated perfusion
with conventional surgical methods. Some patients are ruled-out because the size
or location of the tumor makes mobilization and cannulation of the liver
impossible. Others have co-existent medical conditions that make the surgery an
unacceptable risk. Still others who might benefit from a second procedure are no
longer treatable with surgical perfusion due to the extensive scar tissue that
develops around the liver after the initial procedure."

Dr. Alexander added, "Our hope is that the Delcath system will provide a far
less invasive way to administer high dose melphalan perfusion therapy, expanding
the treatment options for patients with inoperable, life-limiting cancer of the
liver."

According to Delcath estimates, approximately 222,000 Americans each year are
diagnosed with cancer of the liver. Roughly seven percent have primary liver
cancer; the balance develop the condition as a result of cancer metastasizing,
or spreading, from another point source, such as melanoma, breast, prostate or
colorectal cancers.

Delcath is especially excited about the potential for this new melphalan
treatment to provide a new treatment alternative for patients with metastases
from colorectal disease. NCI researchers have reported that of the 140,000 new
patients diagnosed with colorectal cancer in the US annually, 20-30 percent will
die of progressive metastatic disease confined to the liver, usually within
12-24 months of diagnosis.

                                      -3-


Delcath Systems is the leading developer of isolated perfusion technology for
organ or region-specific delivery of therapeutic agents. Its technology is
covered by seven US and three foreign issued patents. The Company is
headquartered in Stamford, CT.

This release contains "forward-looking statements" based on current expectations
but involving known and unknown risks and uncertainties. Actual results or
achievements may be materially different from those expressed or implied.
Delcath plans and objectives are based on assumptions involving judgments with
respect to future economic, competitive and market conditions, its ability to
consummate, and the timing of, acquisitions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond its control. Therefore, there can be no assurance than any
forward-looking statement will prove to be accurate.




                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                        DELCATH SYSTEMS, INC.



Dated:  June 12, 2001         By:  /s/ M.S. Koly
                                 --------------------------------------
                                 M.S. Koly
                                 President and Chief Executive Officer